Abstract:The prognostic value of p16 for survival of patients with non-small cell lung cancer (NSCLC) remains controversial. we performed a meta-analysis of the literatures in order to clarify its impact. Published studies in English were identified using an electronic search in order to aggregate the available survival results. To be eligible, a study had to have dealt with p16 protein assessment in NSCLC patients on the primary site and have reported survival data according to p16 expression. Twenty trials, comprising 1995 patients, provided sufficient information for the meta-analysis. Seventeen assessed any non-small cell lung cancer subtype, three assessed adenocarcinoma only. Eight identified high p16 expression as a favourable prognostic factor and one linked it with poor prognosis, Eleven trials were not significant. The overall combined hazard ratio (HR) calculated using a random-effects model suggested that high p16 expression has a favourable impact on survival in all NSCLC [0.69, 95% CI: 0.59–0.81]; The studies were categorized according to histology, disease stage and laboratory technique. The aggregated survival data showed a poor survival prognosis in squamous cell cancer with lower p16 expression [0.34, 95% CI: 0.13–0.91]. The adenocarcinoma subgroup had an HR of 0.91 [95% CI 0.76–1.10] without statistical significance. In early stage NSCLC (I–II), the aggregated HR was 0.42 [95% CI: 0.28–0.63], showing a worse survival for NSCLC with abnormal p16 expression; Results were significant with the HR of 0.61 [95% CI: 0.45–0.82] for five studies detecting p16 by immunohistochemistry with antibody clone G175–405. In conclusion, our meta-analysis shows that the p16 expression status is an independent prognostic factor in NSCLC, and this tendency is also found in the subgroups of squamous cell lung cancer and early stage NSCLC (I–II), but not in lung adenocarcinoma.

Study of CDKN2/p16 Gene Existence State in Lung Cancer

Analysis on point mutation of the CDKN2/p16 gene in lung cancer

Deletion of P16 gene exon 2 in bronchofibroscopic brush-off cells of human lung carcinoma

Homozygous deletion of p15、 p16 genes in lung cancer

STUDY ON THE METHYLATION OF P16 GENE AND GENETIC POLYMORPHISM OF GSTM1 GENE RELATED WITH SUSCEPTIBILITY TO NON-SMALL CELL LUNG CANCER

The effects of p16 gene methylation on the risk of non-small cell lung cancer

[Abnormality of p16 gene and its clinicopathological significance in non-small cell lung cancer].

[Mutation Analysis of P16 Gene in Non-Small Cell Lung Carcinomas].

Characterization of a base-resolution common deletion region within CDKN2A gene in cancers and its biological and clinical significances

Expression of p16 and Ki67 and their correlation with prognosis in non-small cell lung cancer

Study on the Expressions and Clinical Significances of P16ink4a Protein in 103 Cases of Non-Small Cell Lung Cancer

EXPRESSION OF THE p16 AND Rb GENES mRNA AND PROTEIN LEVELS IN LUNG CANCER

Early Diagnosis of Lung Carcinoma :A Correlative Study of P53 、p16protein Expression to CT Appearance in Lung Carcinoma

Homozygous deletion of p16 and p15 genes in laryngeal squamous cell carcinoma]

Study of Relatonship Between the Expression of P16 Protein and CT Characteristics in Lung Peripheral Adenocarcinoma

P1.02-049 Detection of CDKN2A Gene Mutations in Patients with Non-Small Cell Lung Cancer Patients

[Study of Deletion and Mutation of P16 Gene in Primary Hepatocellular Carcinoma].

Alterations of Cdkn2(P16/Mts1) Exon 2 in Human Hepatocellular Carcinoma

Relationship Between Deletion of GSTM1, GSTT1 Genes and Susceptibility to Lung Cancer

Expression of P16 in Non-Small Cell Lung Cancer and Its Prognostic Significance: a Meta-Analysis of Published Literatures.

Cloning and Application of Human P16ink4 Cdna Probe in the Study of Non-small Cell Lung Cancer